miR-191 promotes radiation resistance of prostate cancer through interaction with RXRA. [electronic resource]
Producer: 20201005Description: 107-117 p. digitalISSN:- 1872-7980
- Alitretinoin -- administration & dosage
- Animals
- Antineoplastic Agents -- administration & dosage
- Biomarkers, Tumor -- metabolism
- Cell Line, Tumor
- Chemoradiotherapy, Adjuvant -- methods
- Disease-Free Survival
- Down-Regulation
- Gene Expression Regulation, Neoplastic -- drug effects
- Gene Knockdown Techniques
- Humans
- Kallikreins -- blood
- Kaplan-Meier Estimate
- Male
- Mice
- MicroRNAs -- agonists
- Middle Aged
- Neoplasm Grading
- Neoplasm Recurrence, Local -- blood
- Primary Cell Culture
- Prognosis
- Prostate -- pathology
- Prostate-Specific Antigen -- blood
- Prostatectomy
- Prostatic Neoplasms -- blood
- Radiation Tolerance -- drug effects
- Retinoid X Receptor alpha -- agonists
- Survival Rate
- Time Factors
- Xenograft Model Antitumor Assays
No physical items for this record
Publication Type: Journal Article; Research Support, Non-U.S. Gov't
There are no comments on this title.
Log in to your account to post a comment.